A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Trial Profile

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 09 Dec 2017 According to a Janssen Research & Development media release, results of pooled analysis from SPARK, PCYC-1104, RAY and CAN3001 studies (n=370) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition.
    • 09 Dec 2017 According to an AbbVie media release, results of pooled analysis from SPARK, PCYC-1104, RAY and CAN3001 studies (n=370) will be presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition.
    • 09 Dec 2017 Results of pooled analysis from SPARK, PCYC-1104, RAY and CAN3001 studies (n=370) published in an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top